Of interest, these HER2-overexpressing patients had previously received trastuzumab, a HER2-directed monoclonal antibody, as their standard-of-care chemotherapy regimen, suggesting that prior trastuzumab therapy may sensitize tumor cells to cell-mediated lysis triggered by GP2. This evidence concerns the gene ERBB2 and neoplasm.